A novel testosterone 2% gel for the treatment of hypogonadal males

Journal of Andrology

Volumn 33, Issue 4, 2012, Pages 601-607

  Dobs, Adrian S ^a   Mcgettigan, John ^b   Norwood, Paul ^c   Howell, Julian ^d   Waldie, Elizabeth ^d   Chen, Yusong ^e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Quality of Life Medical and Research Center LLC   (United States)

^c Valley Endocrine and Valley Research   (United States)

^d ProStrakan   (United Kingdom)

^e ENDO PHARMACEUTICALS INC   (United States)

Author keywords

Androgen; Hypogonadism; Testosterone deficiency; Testosterone replacement

Indexed keywords

ITNOGEN; TESTOSTERONE; TOSTRAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTACT DERMATITIS; CONTUSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EPIGASTRIC DISCOMFORT; GASTRIC HYPOMOTILITY; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRIORITY JOURNAL; SKIN MANIFESTATION; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; GELS; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; TESTOSTERONE;

EID: 84866073053     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.111.014308     Document Type: Article

References (11)

1. ® 1% (testosterone gel). Prescribing Information. September 2009. http://www.testim.com/pdf/ Testim_PI_Medication_Guide.pdf. Accessed April 17, 2012.
2. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559.
3. ® (testosterone topical solution). Prescribing Information. December 2011. http://pi.lilly.com/us/axiron-pi.pdf. Accessed April 17, 2012.
4. McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int. 2003;91(1):69-74.
5. Seftel A. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents. Int J Impot Res. 2007;19:2-24.
6. ® (testosterone gel) 1%. Prescribing information. November 2011. http://www.rxabbott. com/pdf/androgel_PI.pdf. Accessed April 17, 2012.
7. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R; North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003;88(6):2673-2681.
8. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510.
9. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab. 2000;85(3):964-969.
10. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FCW. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res. 2009;21:1-8.
11. Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab. 2006;91:4335-4343.